Quantcast

Latest Novo Nordisk Stories

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-06 08:25:22

Diabetes leader nominated by Plainsboro's Mayor Peter Cantu PLAINSBORO, N.J., June 6, 2014 /PRNewswire/ -- Novo Nordisk, a global health care company with more than 90 years of innovation and leadership in diabetes care, will be presented today with a 2014 New Good Neighbor Award for its new LEED Silver certified US headquarters in Plainsboro, New Jersey. The company was given this award based on a variety of factors, including economic benefit/job creation, architectural merit, and...

2014-06-04 08:29:58

MISSISSAUGA, ON, June 4, 2014 /CNW/ - Novo Nordisk today announces that the Québec government has approved the inclusion of Victoza(®) (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue, to the Lists of Medications, effective June 2, 2014. The reimbursement of Victoza(®) by the Québec Health Insurance Board (RAMQ) will allow people living with type 2 diabetes to have access to a treatment to help better manage diabetes. Québec is the first...

2014-05-31 23:04:47

Market Size - $4.9 bn in 2013, Market Growth - CAGR of 17.6%, Market Trends – Substitution of human insulin by analogs new report by Grand View Research. View complete report with TOC - http://www.grandviewresearch.com/industry-analysis/asia-pacific-insulin-market. San Francisco, California (PRWEB) May 31, 2014 The Asia Pacific market for Insulin is expected to reach USD 15.04 billion by 2020, according to a new study by Grand View Research, Inc. Growing regional prevalence of diabetes,...

2014-05-21 08:29:22

DUBLIN, May 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/78cbh2/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Vaginal atrophy is defined as a decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after menopause. Up to...

2014-05-05 20:26:32

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/diseases/bleeding_disorders_world_pharmaceutical_industry_market_2014_2024.htmlReport DetailsTreating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecastsTreatments for bleeding - what're their prospects? Visiongain's new report gives you...

2014-04-29 23:08:51

Changes in preference towards the use of insulin pens will spur double-digit market growth by 2020, reports iData Research Vancouver, BC (PRWEB) April 29, 2014 According to a new report series by iData Research [http://www.idataresearch.com , the leading global authority in medical device and pharmaceutical market research, the U.S. market for diabetes diagnosis, treatment and drug delivery will reach $25 billion by 2020, from almost $17 billion in 2013, with Sanofi, Novo Nordisk and Eli...

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...

2014-04-17 08:27:42

To support continued development of NT100, including addition of Ph2 RESPONSE trial in recurrent pregnancy loss indication PALO ALTO, Calif., April 17, 2014 /PRNewswire/ -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the closing of an $18 million Series B financing. The proceeds will be used to expand the development of Nora's lead drug, NT100, including the addition of a second Phase...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.